The Lipid Panel: Beyond Total Cholesterol

What Each Value Is

Total cholesterol. The sum of cholesterol in all lipoprotein fractions, atherogenic and protective combined. Because it includes HDL, a high total can reflect high HDL rather than high risk, which is why it has largely been superseded in risk assessment.

LDL cholesterol. Usually calculated by the Friedewald equation, which subtracts HDL and triglycerides divided by five from total cholesterol. That equation becomes unreliable when triglycerides exceed roughly 4.5 mmol/L, and it underestimates LDL at low LDL values. Newer equations perform better, and direct LDL measurement is available.

HDL cholesterol. Inversely associated with cardiovascular risk observationally, and raising it pharmacologically has repeatedly failed to reduce events, which is why HDL is now regarded as a risk marker rather than a target. Very high HDL has been associated with higher mortality in some analyses.

Triglycerides. Reflect recent intake and metabolic state. Highly responsive to diet, alcohol and insulin resistance, and requiring a genuine fast for standard interpretation.

Non-HDL cholesterol. Total minus HDL, capturing all atherogenic fractions. Free, requires no fasting, and correlates well with apolipoprotein B. Reported by some laboratories and easy to calculate.

The Two Free Derivations

The triglyceride to HDL ratio is the most practically useful, because it identifies a pattern the raw values conceal. High triglycerides with low HDL indicates insulin resistance and a shift toward small dense LDL particles, which means more particles per unit of LDL cholesterol and therefore higher risk than the LDL number suggests.

Thresholds depend on units. Above roughly 2 using mg/dL, or above about 0.9 using mmol/L, suggests insulin resistance, with meaningful variation across ethnic groups.

Remnant cholesterol deserves more attention than it gets. Triglyceride-rich remnant particles are atherogenic, and remnant cholesterol has emerged as an independent risk marker in several analyses, calculable free from a standard panel.

Why ApoB Is Better, and When to Use What

Every atherogenic particle carries exactly one apolipoprotein B molecule, so apoB counts particles. Since particle entry into the arterial wall is the causal exposure, apoB measures it more directly than any cholesterol measure.

The practical case is discordance. LDL cholesterol and apoB agree in most people and diverge in a substantial minority, particularly with insulin resistance, high triglycerides or small dense particles. In discordant cases, risk tracks apoB, which means an acceptable LDL cholesterol with a raised apoB is false reassurance.

ApoB is inexpensive, standardised, and does not require fasting. Guideline positions increasingly recognise it as a preferred measure, and it remains absent from most standard panels.

The practical hierarchy: apoB if available, non-HDL cholesterol if not, and LDL cholesterol as the least informative of the three. Add lipoprotein(a) once in a lifetime, which is a separate particle not captured by any of the above.

NMR particle counting measures a similar quantity to apoB at higher cost with less standardisation, and generally adds little where apoB is available.

Fasting, Timing and Assay Issues

Fasting. Guidelines have moved toward non-fasting lipid panels for routine assessment, since non-fasting samples predict risk as well and are more convenient. Triglycerides are the value most affected, rising after meals, so a fasting sample is preferred where triglycerides specifically are being assessed or where they are markedly raised.

Biological variation. Within-person variation in lipids is substantial, on the order of 5 to 10 per cent for cholesterol measures and considerably more for triglycerides. A single panel should not drive a major decision, and two measurements are better.

Things that shift the panel: acute illness lowers cholesterol for weeks, so a panel after infection or hospital admission underestimates; recent alcohol raises triglycerides substantially; weight change in either direction shifts values; pregnancy raises them; hypothyroidism raises LDL, which is why thyroid function belongs alongside; and posture and tourniquet time have small effects.

After a cardiac event, lipids measured in the days following are lower than baseline, which has led to under-management historically.

Reading the Panel in Context

High LDL with everything else normal, no other risk factors. Consider familial hypercholesterolaemia if markedly raised, particularly with a family history of premature disease, since it is common, under-identified and responds well to therapy. Also check thyroid function.

High triglycerides with low HDL and central adiposity. Insulin resistance. The lipid abnormality is downstream, and the intervention is metabolic.

Very high triglycerides, above roughly 10 mmol/L, is a pancreatitis risk and a clinical situation.

Low LDL with low total cholesterol in an unwell person. Can reflect illness, malabsorption, hyperthyroidism or liver disease rather than a favourable profile.

Isolated low HDL. Common, associated with insulin resistance and inactivity, and not a target in itself since raising it pharmacologically does not help.

Everything acceptable but a family history of premature disease. Measure lipoprotein(a) and apoB, and consider a calcium score. This is where a standard panel most often provides false reassurance.

The general point: the lipid panel is a starting point rather than a conclusion, and the two derivations plus apoB and a once-in-a-lifetime Lp(a) turn it into a genuinely informative assessment.

What Moves These Numbers

Triglycerides, the most responsive value on the panel. Reducing alcohol, refined carbohydrate and total energy intake lowers them substantially, as does omega-3 at 2 g or more of EPA and DHA and improving insulin sensitivity through exercise and adiposity reduction.

LDL and apoB. Reducing saturated fat intake modestly, soluble fibre, plant sterols at 2 g daily, and weight loss. Statins, ezetimibe and PCSK9 inhibitors reduce them substantially where indicated, and the medication effect is roughly an order of magnitude larger than the dietary one.

HDL. Exercise, smoking cessation and weight loss raise it modestly. Not worth targeting.

Lipoprotein(a). Nothing available currently, which is why it is measured once and used to calibrate urgency.

What to re-measure and when: six to twelve weeks after a dietary or medication change for triglycerides and apoB, since both respond in that window. Annually thereafter.

The honest framing is that where apoB reduction is genuinely needed for risk, dietary measures help and rarely suffice, and that is a clinical conversation rather than a supplement one.